Diagnosis of GH deficiency as a late effect of radiotherapy in survivors of childhood cancers

Jad G. Sfeir, Nana Esi N. Kittah, Shrikant U. Tamhane, Sina Jasim, Wassim Chemaitilly, Laurie E. Cohen, Mohammad H Murad

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Limited guidance exists for selecting a laboratory method for diagnosing GH deficiency (GHD) when it occurs as a late effect of radiotherapy in childhood cancer survivors (CCSs). Methods: We searched Medline, Embase, Cochrane Central Register of Controlled Trials and Database of Systematic Reviews, and Scopus for studies evaluating GHD that used IGF-1 or IGF-binding protein 3 (IGFBP-3) measurements compared with GH dynamic testing. Results: We included 15 studies [IGF-1 (8 studies) and IGFBP-3 (7 studies)] enrolling 477 patients. Comparator tests varied widely. Overall, both IGF-1 and IGFBP-3 had suboptimal diagnostic accuracy but were strongly correlated. The use of both tests simultaneously in the same cohort did not improve the diagnostic accuracy. Despite high variability in the testing protocols, dynamic tests remained the most accurate for appropriately identifying patients with GHD. The insulin tolerance test (ITT) appears to be the most accepted reference test when used alone or in combination with arginine; however, standardized testing strategies among practice groups are absent. GHRH and arginine stimulation performed almost similarly to the ITT; however, in one study GHRH with arginine stimulation had 66% sensitivity and 88% specificity compared with the ITT. Insufficient data were available to assess the accuracy of serial GH testing (nocturnal or over 24 hours). Conclusion: The diagnostic accuracy of various dynamic tests for GHD in CCSs appears to follow the same patterns as those in non-CCSs. Interpreting GHRH stimulation is a challenge given the primarily hypothalamic dysfunction in CCSs. IGF-1 and IGFBP-3 perform poorly in this population.

Original languageEnglish (US)
Pages (from-to)2785-2793
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume103
Issue number8
DOIs
StatePublished - Jan 1 2018

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Radiotherapy
Insulin-Like Growth Factor I
Survivors
Arginine
Testing
Insulin
Neoplasms
Databases
Sensitivity and Specificity
Population

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Diagnosis of GH deficiency as a late effect of radiotherapy in survivors of childhood cancers. / Sfeir, Jad G.; Kittah, Nana Esi N.; Tamhane, Shrikant U.; Jasim, Sina; Chemaitilly, Wassim; Cohen, Laurie E.; Murad, Mohammad H.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 103, No. 8, 01.01.2018, p. 2785-2793.

Research output: Contribution to journalArticle

Sfeir, Jad G. ; Kittah, Nana Esi N. ; Tamhane, Shrikant U. ; Jasim, Sina ; Chemaitilly, Wassim ; Cohen, Laurie E. ; Murad, Mohammad H. / Diagnosis of GH deficiency as a late effect of radiotherapy in survivors of childhood cancers. In: Journal of Clinical Endocrinology and Metabolism. 2018 ; Vol. 103, No. 8. pp. 2785-2793.
@article{518ed2bdda7e4ed5b805ab28b134e052,
title = "Diagnosis of GH deficiency as a late effect of radiotherapy in survivors of childhood cancers",
abstract = "Background: Limited guidance exists for selecting a laboratory method for diagnosing GH deficiency (GHD) when it occurs as a late effect of radiotherapy in childhood cancer survivors (CCSs). Methods: We searched Medline, Embase, Cochrane Central Register of Controlled Trials and Database of Systematic Reviews, and Scopus for studies evaluating GHD that used IGF-1 or IGF-binding protein 3 (IGFBP-3) measurements compared with GH dynamic testing. Results: We included 15 studies [IGF-1 (8 studies) and IGFBP-3 (7 studies)] enrolling 477 patients. Comparator tests varied widely. Overall, both IGF-1 and IGFBP-3 had suboptimal diagnostic accuracy but were strongly correlated. The use of both tests simultaneously in the same cohort did not improve the diagnostic accuracy. Despite high variability in the testing protocols, dynamic tests remained the most accurate for appropriately identifying patients with GHD. The insulin tolerance test (ITT) appears to be the most accepted reference test when used alone or in combination with arginine; however, standardized testing strategies among practice groups are absent. GHRH and arginine stimulation performed almost similarly to the ITT; however, in one study GHRH with arginine stimulation had 66{\%} sensitivity and 88{\%} specificity compared with the ITT. Insufficient data were available to assess the accuracy of serial GH testing (nocturnal or over 24 hours). Conclusion: The diagnostic accuracy of various dynamic tests for GHD in CCSs appears to follow the same patterns as those in non-CCSs. Interpreting GHRH stimulation is a challenge given the primarily hypothalamic dysfunction in CCSs. IGF-1 and IGFBP-3 perform poorly in this population.",
author = "Sfeir, {Jad G.} and Kittah, {Nana Esi N.} and Tamhane, {Shrikant U.} and Sina Jasim and Wassim Chemaitilly and Cohen, {Laurie E.} and Murad, {Mohammad H}",
year = "2018",
month = "1",
day = "1",
doi = "10.1210/jc.2018-01204",
language = "English (US)",
volume = "103",
pages = "2785--2793",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - Diagnosis of GH deficiency as a late effect of radiotherapy in survivors of childhood cancers

AU - Sfeir, Jad G.

AU - Kittah, Nana Esi N.

AU - Tamhane, Shrikant U.

AU - Jasim, Sina

AU - Chemaitilly, Wassim

AU - Cohen, Laurie E.

AU - Murad, Mohammad H

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Limited guidance exists for selecting a laboratory method for diagnosing GH deficiency (GHD) when it occurs as a late effect of radiotherapy in childhood cancer survivors (CCSs). Methods: We searched Medline, Embase, Cochrane Central Register of Controlled Trials and Database of Systematic Reviews, and Scopus for studies evaluating GHD that used IGF-1 or IGF-binding protein 3 (IGFBP-3) measurements compared with GH dynamic testing. Results: We included 15 studies [IGF-1 (8 studies) and IGFBP-3 (7 studies)] enrolling 477 patients. Comparator tests varied widely. Overall, both IGF-1 and IGFBP-3 had suboptimal diagnostic accuracy but were strongly correlated. The use of both tests simultaneously in the same cohort did not improve the diagnostic accuracy. Despite high variability in the testing protocols, dynamic tests remained the most accurate for appropriately identifying patients with GHD. The insulin tolerance test (ITT) appears to be the most accepted reference test when used alone or in combination with arginine; however, standardized testing strategies among practice groups are absent. GHRH and arginine stimulation performed almost similarly to the ITT; however, in one study GHRH with arginine stimulation had 66% sensitivity and 88% specificity compared with the ITT. Insufficient data were available to assess the accuracy of serial GH testing (nocturnal or over 24 hours). Conclusion: The diagnostic accuracy of various dynamic tests for GHD in CCSs appears to follow the same patterns as those in non-CCSs. Interpreting GHRH stimulation is a challenge given the primarily hypothalamic dysfunction in CCSs. IGF-1 and IGFBP-3 perform poorly in this population.

AB - Background: Limited guidance exists for selecting a laboratory method for diagnosing GH deficiency (GHD) when it occurs as a late effect of radiotherapy in childhood cancer survivors (CCSs). Methods: We searched Medline, Embase, Cochrane Central Register of Controlled Trials and Database of Systematic Reviews, and Scopus for studies evaluating GHD that used IGF-1 or IGF-binding protein 3 (IGFBP-3) measurements compared with GH dynamic testing. Results: We included 15 studies [IGF-1 (8 studies) and IGFBP-3 (7 studies)] enrolling 477 patients. Comparator tests varied widely. Overall, both IGF-1 and IGFBP-3 had suboptimal diagnostic accuracy but were strongly correlated. The use of both tests simultaneously in the same cohort did not improve the diagnostic accuracy. Despite high variability in the testing protocols, dynamic tests remained the most accurate for appropriately identifying patients with GHD. The insulin tolerance test (ITT) appears to be the most accepted reference test when used alone or in combination with arginine; however, standardized testing strategies among practice groups are absent. GHRH and arginine stimulation performed almost similarly to the ITT; however, in one study GHRH with arginine stimulation had 66% sensitivity and 88% specificity compared with the ITT. Insufficient data were available to assess the accuracy of serial GH testing (nocturnal or over 24 hours). Conclusion: The diagnostic accuracy of various dynamic tests for GHD in CCSs appears to follow the same patterns as those in non-CCSs. Interpreting GHRH stimulation is a challenge given the primarily hypothalamic dysfunction in CCSs. IGF-1 and IGFBP-3 perform poorly in this population.

UR - http://www.scopus.com/inward/record.url?scp=85055271061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055271061&partnerID=8YFLogxK

U2 - 10.1210/jc.2018-01204

DO - 10.1210/jc.2018-01204

M3 - Article

C2 - 29982753

AN - SCOPUS:85055271061

VL - 103

SP - 2785

EP - 2793

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 8

ER -